Vol. 31 No. 2
March-April 2009

Analogue-based Drug Discovery II

Analogue-based drug discovery has a very important role in drug research. The first project under the same title afforded a book published by Wiley-VCH in 2006. It was well received (e.g., see M. Cowart, J. Med. Chem. 2006, 49, 4799), and all the copies were sold within 18 months.

This positive feedback of the medicinal chemistry community encouraged the editors to continue this work with new topics. The second volume, to be published in early 2010, will contain the following chapters:

I. General Aspects

1. Optimizing Therapy by Analogues (J. Fischer, C.R. Ganellin, E.M. Alapi)
2. Analogues and Standalone Drugs (J. Fischer, C.R. Ganellin, A. Ganesan, J. Proudfoot)
3. Lead and Drug Optimization (J. Fischer, C.R. Ganellin, and J. Proudfoot)
4. Molecular Modeling in ABDD (G. Ferenczy)
5. The Impact of Natural Products upon Modern Drug Discovery (A. Ganesan)
6. Monoterpenoid Indole Alkaloids (A. Nemes)
7. Paclitaxel Analogue (P. Erhardt and M. El-Dakdouki)
8. Issues for Patenting of Analogues (S. Smith)

II. Analogue Classes

1. Beta2 Agonists (G. Gaviraghi)
2. M3 Muscarinic Antagonists (M. Grauert, P. Casarosa, M.P. Pieper)
3. SSRIs (D. Rotella and W.E. Childers)
4. Progestogens (Z. Tuba , S. Maho, J. Csorgei, and C. Molnar)
5. DPP-IV Inhibitors (J.U. Peters, P. Mattei)
6. PDE5 Inhibitors (H. Haning, E. Bischoff)
7. Serotonin and Norepinephrine Reuptake Inhibitors (M. Abou-Gharbia and W. Childers)
8. Anthracyclines (F.A. Arcamone)
9. Rifampicin analogues (E. Selva and G. Lancini)

III. Case Studies

1. Eplerenone (J. Kalvoda and M. De Gasparo)
2. Lapatinib (K. Lackey)
3. Dasatinib (J. Das and J.C. Barrish)
4. Conazoles (J. Heeres, P. Lewi, L. Meerpoel)
5. Clevudine (C.K. Chu)
6. Rasagiline (M. Youdim)
7. Liraglutide (L.B. Knudsen)
8. Tipranavir (S. Thaisrivongs, J. Strohbach, S. Turner)
9. Rilpivirine (J. Guillemont and J. Heeres)

The second volume will discuss a broad spectrum of discoveries of anticancer, antifungal, antiviral, cardiovascular, CNS, diuretic, hormonal, respiratory, and diabetes type 2 drugs. The majority of the authors, who come from 10 different countries, were also involved as inventors. This IUPAC project started in May 2008. According to the planned contents, 42 authors will participate.

For further information and comments, contact János Fischer <[email protected]> or C. Robin Ganellin <[email protected]>.

www.iupac.org/web/ins/2008-013-1-700